Genestra Formula OSX- 90 tablets

Free Shipping..
Price: 
$22.60
Average: 5 (1 vote)
Vendor Code: 
05250
Brand: 

Verifiable Logos

Genestra Formula OSX- 90 tablets

Suggested Retail: $19.65

• Calcium and magnesium formulation in a 2:1 ratio with vitamin D and additional minerals
• Helps in the development and maintenance of bones and teeth(1)
• Helps in tissue formation(2)
• Easy-to-use
• Two daily tablets increase patient compliance

Formula OSX provides calcium from microcrystalline hydroxyapatite along with magnesium and synergistic nutrients to help in the development and maintenance of bones and teeth and to help in tissue formation.(2)

References:
1. NHPD Monograph on Multi-Vitamin and Mineral. October 2007.
2. NHPD Monograph on Multi-Vitamin and Mineral. October 2007.

Additional product info:
Calcium and the vitamin D hormonal system are both essential for the development and maintenance of skeletal health. Calcium plays a vital role in neuromuscular function, many enzyme-mediated processes, blood clotting and in providing rigidity to the skeleton by virtue of its phosphate salts. Over 99% of the body’s calcium is stored in the bone, where, apart from providing mechanical strength, it serves as a mineral reservoir that can be drawn upon to maintain normal plasma calcium. Vitamin D is required to maintain normal blood levels of calcium and phosphate, which are in turn needed for the normal mineralization of bone, muscle contraction, nerve conduction and the general cellular functioning of all body cells. Vitamin D, derived from both endogenous (skin) and exogenous (diet) sources, is converted into 25OHD in the liver and then into 1,25(OH)2D in the kidneys. The latter metabolite controls calcium absorption. However, plasma 25OHD closely reflects vitamin D nutritional status, and because it is the substrate for the renal enzyme that produces 1,25(OH)2D, it could have mainly an indirect and also a direct effect on calcium absorption. A vitamin D shortage would reduce the intestinal absorption of calcium, which could worsen if the diet is deficient of this element. Osteoporosis and its clinical consequence, fragility fractures, are now recognized as major public health problems. Bone mass declines and the risk of fractures increases as people age, especially postmenopausal women. An adequate intake of calcium and vitamin D, including supplementation, has been advocated as a universal primary intervention in the prevention and treatment of high-risk patients. Evidence shows that there is still a high proportion of people with inappropriately low calcium and vitamin D intake and serum levels. For selective groups of people, such as the elderly (frequently older than 70 years), those with low solar exposure and in generally poor or inadequate nutritional condition, guaranteeing a daily intake of at least 1 g of calcium and 700–800 IU of vitamin D with supplements would have beneficial effects on bone health. In those individuals with a high risk of osteoporotic fracture, calcium and vitamin D supplements are necessary but frequently insufficient.(3) The Women’s Health Initiative (WHI) clinical trial randomly assigned 36,282 postmenopausal women to receive 1000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily or placebo for an average follow-up period of 7.0 years. Significantly higher hip bone density but a non-significant reduction (12 percent) in the rate of hip fracture among those assigned to calcium with vitamin D were observed.(4) A recent review discusses vitamin D status and supplementation when treating patients with osteoporosis in relation to risks and prevention of falls and fractures. The authors conclude that poor vitamin D status and low calcium intake are important determinates for osteoporosis and fracture risk. Based on evidence from literature, adequate supplementation with at least 700 IU of vitamin D, preferably cholecalciferol, is required for improving physical function and prevention of falls and fractures. Additional calcium supplementation may be considered when dietary calcium intake is below 700 mg/day, with a supplementation dose that leads to a maximum total daily calcium intake of 1000 to 1200 mg.(5) Microcrystalline calcium hydroxyapatite compound (MCHC; Ossopan) is a naturally derived calcium extract of bone. As well as calcium and phosphate, MCHC contains many other minerals in approximately physiological proportions together with various other organic constituents of bone. Evidence that MCHC is better absorbed than other calcium supplements has led to various clinical applications. Reports have suggested that oral MCHC can accelerate fracture healing , and improve or prevent osteoporosis. A pilot study demonstrated that treatment with oral MCHC (8 grams/day) and small doses of dihydrotachysterol (DHT) resulted in an immediate positive calcium balance which appears to be sustained for long periods of continuing treatment, thus confirming previous reports that the minerals in this product are available for absorption. The authors have also confirmed in one case the superiority of this treatment over soluble supplements such as calcium gluconate.(6) Calcium supplements in postmenopausal women with a low calcium intake have been shown to prevent osteoporotic vertebral fracture, but calcium is variably absorbed and often poorly tolerated, which may limit effectiveness. A study compared the efficacy and tolerability of 500 mg/day of calcium in the form of ossein-hydroxyapatite (OHC) versus 500 mg/day of tricalcium phosphate (TCP) and placebo in the prevention of postmenopausal bone loss. This was a prospective randomized study enrolling 153 postmenopausal osteopenic women. Serum and urine markers of bone turnover were collected at 3 and 6 months. Bone density measurement was performed at baseline and 6 months in all participants, and at 12 months in women taking OHC. While both OHC and TCP were well tolerated and significantly reduced bone turnover markers, the effect of osseinhydroxyapatite seems slightly superior to that of tricalcium phosphate.(7)

References:
3. Díaz-López B, Cannata-Andía JB. Supplementation of vitamin D and calcium: advantages and risks. Nephrol Dial Transplant. 2006 Sep;21(9):2375-7. Page 2375, Introduction, 1st, 3rd and 4th paragraphs; Page 2376, last 2 paragraphs
4. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SA, Black HR, Blanchette P, Bonds DE, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D; Women's Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006 Feb 16;354(7):669-83. Page 669, Abstract; Page 680, Discussion, last paragraph; Page 680, Conclusion
5. van den Bergh JP, Bours SP, van Geel TA, Geusens PP. Optimal use of vitamin D when treating osteoporosis. Curr Osteoporos Rep. 2011 Mar;9(1):36-42. Page 36, Abstract; Page 40, Conclusion
6. Dent CE, Davies IJ. Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol. J R Soc Med. 1980 Nov;73(11):780-5.
7. Albertazzi P, Steel SA, Howarth EM, Purdie DW. Comparison of the effects of two different types of calcium supplementation on markers of bone metabolism in a postmenopausal osteopenic population with low calcium intake: a double-blind placebo-controlled trial. Climacteric. 2004 Mar;7(1):33-40. Abstract
8. Herr C, Greulich T, Koczulla RA, Meyer S, Zakharkina T, Branscheidt M, Eschmann R, Bals R. The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer. Respir Res. 2011 Mar 18;12:31. Page 4, 2nd paragraph
9. Laaksi I, Ruohola JP, Mattila V, Auvinen A, Ylikomi T, Pihlajamäki H. Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. J Infect Dis. 2010 Sep 1;202(5):809-14. Page 810, Subjects and Methods, 1st paragraph; Page 811, Discussion, 1st paragraph; Page 813, Conclusion
10. Dimai HP, Porta S, Wirnsberger G, Lindschinger M, Pamperl I, Dobnig H, Wilders-Truschnig M, Lau KH. Daily oral magnesium supplementation suppresses bone turnover in young adult males. J Clin Endocrinol Metab. 1998 Aug;83(8):2742-8. Abstract; Page 2742, Introduction; Page 2743, 1st paragraph on the right side; Page 2748, Conclusion
11. Aydin H, Deyneli O, Yavuz D, Gözu? H, Mutlu N, Kaygusuz I, Akalin S. Short-term oral magnesium supplementation suppresses bone turnover in postmenopausal osteoporotic women. Biol Trace Elem Res. 2010 Feb;133(2):136-43. Abstract
12. Nielsen FH, Lukaski HC. Update on the relationship between magnesium and exercise. Magnes Res. 2006 Sep;19(3):180-9. Abstract
13. Cinar V, Nizamlioglu M, Mogulkoc R, Baltaci AK. Effects of magnesium supplementation on blood parameters of athletes at rest and after exercise. Biol Trace Elem Res. 2007 Mar;115(3):205-12.

Other ingredients: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, silica, pharmaceutical glaze

Genestra